β-catenin cancer-enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Aug 2022 · 1 min read
In brief
In brief
This study identifies cancer-enhancing genomic regions (CEGRs/ALCDs) as key players in fibrolamellar hepatocellular carcinoma development in young patients. The DNAJB1-PKAc fusion protein activates β-catenin signaling, which interacts with CEGRs to drive oncogene expression and collagen production characteristic of this rare pediatric liver malignancy.
Written by the GCMD Library team from the article.
Statements in this article
Fibrolamellar hepatocellular carcinoma occurs in children and young adults.
The development of FLC is associated with creation of a fusion oncoprotein DNAJB1-PKAc kinase, which activates multiple cancer-associated pathways.
CEGRs/ALCDs are located in multiple oncogenes and cancer-associated genes, regularly silenced in normal tissues.
CEGRs/ALCDs contain regulatory elements in several human cancers outside of pediatric hepatic neoplasms.
The β-catenin-TCF7L2/TCF4 pathway interacts with CEGRs/ALCDs in several human cancers.
FLC-specific genes contain CEGRs/ALCDs.
The fusion oncoprotein DNAJB1-PKAc phosphorylates β-catenin at Ser675, resulting in an increase of β-catenin-TCF7L2/TCF4 complexes.
β-catenin-TCF7L2/TCF4 complexes increase a large family of CEGR/ALCD-dependent collagens and oncogenes.